Investment analysts at Roth Capital started coverage on shares of Bluebird Bio Inc. (NASDAQ:BLUE) in a research note issued to investors on Thursday. The firm set a “buy” rating and a $87.00 price target on the stock. Roth Capital’s target price indicates a potential upside of 17.87% from the company’s current price.

BLUE has been the subject of a number of other research reports. Cantor Fitzgerald began coverage on Bluebird Bio in a research report on Thursday, June 2nd. They issued a “hold” rating and a $42.00 price objective for the company. Jefferies Group reaffirmed a “positive” rating and issued a $80.00 price objective on shares of Bluebird Bio in a research report on Thursday, July 14th. Maxim Group reaffirmed a “buy” rating and issued a $85.00 price objective (down previously from $105.00) on shares of Bluebird Bio in a research report on Thursday, August 4th. Cowen and Company reaffirmed an “outperform” rating on shares of Bluebird Bio in a research report on Friday, September 9th. Finally, Vetr downgraded Bluebird Bio from a “buy” rating to a “hold” rating and set a $44.44 price objective for the company. in a research report on Monday, July 4th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $89.17.

Analyst Recommendations for Bluebird Bio (NASDAQ:BLUE)

Bluebird Bio (NASDAQ:BLUE) traded down 1.6454% during midday trading on Thursday, reaching $72.5955. The company’s stock had a trading volume of 286,136 shares. Bluebird Bio has a 1-year low of $35.37 and a 1-year high of $113.26. The company’s market capitalization is $2.70 billion. The company has a 50 day moving average of $57.02 and a 200-day moving average of $48.11.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/bluebird-bio-inc-blue-earns-buy-rating-from-analysts-at-roth-capital-2.html

Bluebird Bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, August 3rd. The company reported ($1.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.15. Bluebird Bio had a negative return on equity of 24.85% and a negative net margin of 3,512.13%. The company earned $1.55 million during the quarter, compared to analyst estimates of $2.01 million. During the same period last year, the firm earned ($1.57) earnings per share. The business’s revenue was down 68.6% compared to the same quarter last year. Equities research analysts anticipate that Bluebird Bio will post ($6.16) earnings per share for the current fiscal year.

In related news, insider Eric Sullivan sold 2,912 shares of the business’s stock in a transaction dated Wednesday, July 27th. The stock was sold at an average price of $55.01, for a total value of $160,189.12. Following the transaction, the insider now owns 4,456 shares in the company, valued at $245,124.56. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider David Davidson sold 1,000 shares of the business’s stock in a transaction dated Friday, July 15th. The stock was sold at an average price of $45.08, for a total value of $45,080.00. Following the completion of the transaction, the insider now owns 10,600 shares in the company, valued at approximately $477,848. The disclosure for this sale can be found here. 3.50% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Baillie Gifford & Co. boosted its position in Bluebird Bio by 1.5% in the second quarter. Baillie Gifford & Co. now owns 5,054,175 shares of the company’s stock valued at $218,795,000 after buying an additional 76,538 shares during the period. Vanguard Group Inc. boosted its stake in shares of Bluebird Bio by 14.2% in the second quarter. Vanguard Group Inc. now owns 2,680,871 shares of the company’s stock valued at $116,055,000 after buying an additional 333,396 shares during the last quarter. State Street Corp boosted its stake in shares of Bluebird Bio by 41.4% in the second quarter. State Street Corp now owns 1,699,977 shares of the company’s stock valued at $73,592,000 after buying an additional 498,041 shares during the last quarter. BlackRock Fund Advisors boosted its stake in shares of Bluebird Bio by 80.0% in the second quarter. BlackRock Fund Advisors now owns 1,386,229 shares of the company’s stock valued at $60,010,000 after buying an additional 616,095 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new stake in shares of Bluebird Bio during the first quarter valued at about $51,095,000.

About Bluebird Bio

bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.

5 Day Chart for NASDAQ:BLUE

Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.